Results 111 to 120 of about 18,764 (290)

Fixed Point Analysis for Cauchy‐Type Variable‐Order Fractional Differential Equations With Finite Delay

International Journal of Differential Equations, Volume 2026, Issue 1, 2026.
This paper presents a comprehensive analysis of the existence, uniqueness, and Ulam–Hyers stability of solutions for a class of Cauchy‐type nonlinear fractional differential equations with variable order and finite delay. The motivation for this study lies in the increasing importance of variable‐order fractional calculus in modeling real‐world systems
Souhila Sabit, Mohammed Said Souid, Marwa Benaouda, K. Sudarmozhi, Joshua Kiddy K. Asamoah, Amar Nath Chatterjee   +5 more
wiley   +1 more source

Analysis and analytical simulation for a biophysical fractional diffusive cancer model with virotherapy using the Caputo operator

AIMS Biophysics, 2023
In this paper, a biophysical fractional diffusive cancer model with virotherapy is thoroughly analyzed and analytically simulated. The goal of this biophysical model is to represent both the dynamics of cancer development and the results of virotherapy ...
Mohammed Alabedalhadi , Mohammed Shqair, Ibrahim Saleh   +2 more
doaj   +1 more source

The long-term effectiveness and mechanism of oncolytic virotherapy combined with anti-PD-L1 antibody in colorectal cancer patient

Cancer Gene Therapy
Colorectal cancer (CRC) is known to be resistant to immunotherapy. In our phase-I clinical trial, one patient achieved a 313-day prolonged response during the combined treatment of oncolytic virotherapy and immunotherapy.
Hangyu Zhang, Yiqing Ren, Feiyu Wang, Xiaoxuan Tu, Z. Tong, Lulu Liu, Yi Zheng, Peng Zhao, Jinlin Cheng, Jianwen Li, Weijia Fang, Xia Liu   +11 more
semanticscholar   +1 more source

The use of oncolytic virotherapy in the neoadjuvant setting

Journal for ImmunoTherapy of Cancer, 2022
Surgical removal of tumors remains a front-line therapy for many types of cancer. However, this treatment often fails to eradicate disease due to either recurrence of the original tumor or development of distant micrometastases.
Raquela J. Thomas, E. Bartee
semanticscholar   +1 more source

Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy [PDF]

, 2021
Dong Ho Shin, Teresa T. Nguyen, Bülent Özpolat, Frederick F. Lang, Marta M. Alonso, Candelaria Gomez‐Manzano, Juàn Fueyo   +6 more
openalex   +1 more source

Identification of TPRA1 as a Novel Receptor and Predictive Biomarker for Oncolytic Virus M1

Advanced Science, Volume 12, Issue 48, December 29, 2025.
This study identifies transmembrane protein adipocyte‐associated 1 (TPRA1) as a novel receptor for oncolytic virus M1 (OVM). TPRA1's ectodomain binds OVM particles, while its intracellular domain facilitates virus internalization, promoting efficient viral entry.
Linyi Hu, Guigen Zhang, Yuan Lin, Shiming Yi, Jingyu Yang, Xueying Lin, Deli Song, Zhiheng Liu, Jiayu Zhang, Ying Zeng, Shanyu Huang, Zhen Fan, Jifu Zhang, Ying Liu, Cheng Hu, Wenbo Zhu, Wei Yin, Jun Hu, Guangmei Yan, Jing Cai, Jiankai Liang   +20 more
wiley   +1 more source

The Multifaceted Role of Macrophages in Oncolytic Virotherapy

Viruses, 2021
One of the cancer hallmarks is immune evasion mediated by the tumour microenvironment (TME). Oncolytic virotherapy is a form of immunotherapy based on the application of oncolytic viruses (OVs) that selectively replicate in and induce the death of tumour
Laura Hofman, Sean E. Lawler, Martine L. M. Lamfers   +2 more
doaj   +1 more source

Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis. [PDF]

, 2018
Peritoneal metastasis (PM) is an advanced stage malignancy largely refractory to modern therapy. Intraperitoneal (IP) immunotherapy offers a novel approach for the control of regional disease of the peritoneal cavity by breaking immune tolerance.
Bowne, Wilbur B., Katz, Steven C., Khalili, Marian, Morano, William F., Richard, Scott D., Thadi, Anusha   +5 more
core   +2 more sources

The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapy

Frontiers in Immunology
Despite significant advances in our knowledge regarding the genetics and molecular biology of gliomas over the past two decades and hundreds of clinical trials, no effective therapeutic approach has been identified for adult patients with newly diagnosed
A. A. Stepanenko, A. Sosnovtseva, Marat P Valikhov, Anastasia A. Chernysheva, Olga V. Abramova, Victor A. Naumenko, V. Chekhonin   +6 more
semanticscholar   +1 more source

Mathematical Modeling and Optimal Control of Combined Virotherapy and Adoptive T Cell Therapy for Cancer Treatment

Mathematical Methods in the Applied Sciences, Volume 48, Issue 18, Page 16263-16289, December 2025.
ABSTRACT In this study, we investigate the synergistic roles of adoptive T cell therapy (ACT), specifically using tumor‐infiltrating lymphocytes (TILs) and oncolytic virus (OV) therapy in enhancing cancer treatment efficacy. While OVs can initiate tumor destruction, they often fail to achieve complete tumor eradication or generate a strong antitumor ...
Salaheldin Omer, Hermane Mambili‐Mamboundou, Rachid Ouifki   +2 more
wiley   +1 more source